References

1. Kupferberg HJ. Quantitative estimation of diphenylhydantoin, primidone and phenobarbital in plasma by gas-liquid chromatography. Clin Chim Acta 1970;29:282-288.

2. Kupferberg HJ. GLC determination of carbamazepine in plasma. J Pharm Sci 1972; 61:284-286.

3. Pippenger CE, Gillen HW. Gas chromatographic analysis for anticonvulsant drugs in biologic fluids. Clin Chem 1969; 15:582-590.

4. Feldman RG, Pippenger CE. The relation of anticonvulsant drug levels to complete seizure control. J Clin Pharmacol 1976; 16:51-59.

5. Kabra PM, Stafford BE, Marton LJ. Simultaneous measurement of phenobarbital, phenytoin, primidone, ethosuximide, and carbamazepine in serum by high-pressure liquid chromatography. Clin Chem 1977; 23:1284-1288.

6. Turnell DC, Trevor SC, Cooper JD. A rapid procedure for the simultaneous estimation of the anticonvulsant drugs, ethosuximide, phenobarbitone, phenytoin, and carbamazepine in serum using high-pressure liquid chromatography. Ann Clin Biochem 1983; 20 Pt 1:37-40.

7. Datta P, Scurlock D, Dasgupta A. Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue. Ther Drug Monit 2005; 27:305-308.

8. Frank EL, Schwarz EL, Juenke J, Annesley TM, Roberts WL. Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol 2002;118:124-131.

9. Rainey PM, Rogers KE, Roberts WL. Metabolite and matrix interference in phenytoin immunoassays. Clin Chem 1996; 42:1645-1653.

10. Roberts WL, Rainey PM. Interference in immunoassay measurements of total and free phenytoin in uremic patients: a reappraisal. Clin Chem 1993; 39:1872-1877.

11. Roberts WL, Rainey PM. Phenytoin overview-metabolite interference in some immunoassays could be clinically important. Arch Pathol Lab Med 2004; 128:734; author reply: 5.

12. Soldin SJ, Wang E, Verjee Z, Elin RJ. Phenytoin overview-metabolite interference in some immunoassays could be clinically important: results of a College of American Pathologists study. Arch Pathol Lab Med 2003; 127:1623-1625.

13. Datta P, Dasgupta A. Cross-reactivity of fosphenytoin in four phenytoin immunoassays. Clin Chem 1998;44:696-697.

14. Kugler AR, Annesley TM, Nordblom GD, Koup JR, Olson SC. Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays. Clin Chem 1998;44:1474-1480.

15. Roberts WL, De BK, Coleman JP, Annesley TM. Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem 1999; 45:829-837.

16. Dasgupta A, Warner B, Datta P. Use of alkaline phosphatase to correct underestimation of fosphenytoin concentrations in serum measured by phenytoin immunoassays. Am J Clin Pathol 1999; 111: 557-562.

17. Annesley T, Kurzyniec S, Nordblom G, et al. Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin. Clin Chem 2001:46: 910-918.

18. Hallbach J, Vogel H, Guder WG. Determination of lamotrigine, carbamazepine and carbamazepine epoxide in human serum by gas chromatography mass spectrometry. Eur J Clin Chem Clin Biochem 1997; 35:755-759.

19. Jurgens U, May T, Hillenkotter K, Rambeck B. Systematic comparison of three basic methods of sample pretreatment for high-performance liquid chromatographic analysis of antiepileptic drugs using gas chromatography as a reference method. Ther Drug Monit 1984; 6:334-343.

20. Lensmeyer GL. Isothermal gas chromatographic method for the rapid determination of carbamazepine ("tegretol") as its TMS derivative. Clin Toxicol 1977; 11:443-454.

21. Shen S, Elin RJ, Soldin SJ. Characterization of cross reactivity by carbamazepine 10,11-epoxide with carbamazepine assays. Clin Biochem 2001; 34:157-158.

22. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 1986;11:177-198.

23. Fitzgerald BJ, Okos AJ. Elevation of carbamazepine-10, 11-epoxide by quetiapine. Pharmacotherapy 2002; 22:1500-1503.

24. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. The mechanism of the carbamazepine-valproate interaction in humans. Br J Clin Pharmacol 1997; 44:21-27.

25. Robbins DK, Wedlund PJ, Kuhn R, Baumann RJ, Levy RH, Chang SL. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 1990; 29:759-762.

26. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinetic 1996; 31:198-214.

27. Liu H, Delgado MR. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites' concentrations, concentration ratios, and level/dose ratios in epileptic children. Epilepsia 1995; 36:249-254.

28. Pereira LR, Velasco TR, Ceiki-Sakamota A, de Carvalho D. Evaluation of the drug interaction between carbamazepine and lamotrigine in the treatment of refractory epilepsy patients. Rev Neurol 2006; 43:74-77 [Article in Spanish].

29. Theis JG, Sidhu J, Palmer J, Job S, Bullman J, Ascher J. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology 2005; 30:2269-2274.

30. Hugen P, Burger DM, Brinkman K, ter-Hofstede HJ, Schuurman R, Koopmans PP, Hekester YA. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000; 34:465-470.

31. Dasgupta A, Datta P. Analytic performance evaluation of a new turbidimetric immunoassay for carbamazepine on the ADVIA 1650 analyzer: effect of carbamazepine 10,11-epoxide. Ther Drug Monit 2005; 27:31-34.

32. Parant F, Bossu H, Gagnieu MC, Lardet G, Moulsma M. Cross-reactivity assessment of carbamazepine-10,11-epoxide, oxcarbazepine, and 10-hydroxy-carbazepine in two automated carbamazepine immunoassays: PETINIA and EMIT 2000. Ther Drug Monit 2003; 25:41-45.

33. Wilson JF, Tsanaclis LM, Williams J, Tedstone JE, Richens A. Evaluation of assay techniques for the measurement of antiepileptic drugs in serum: a study based on external quality assurance measurements. Ther Drug Monit 1989; 11:185-195.

34. Hermida J, Tutor CJ. How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine 10, 11-epoxide in serum samples? Ther Drug Monit 2003; 25:384-388.

35. Kumps A, Mardens Y. Cross-reactivity assessment of oxcarbazepine and its metabolites in the EMIT assay of carbamazepine plasma levels. Ther Drug Monit 1986; 8:95-97.

36. Parant F, Moulsma M, Gagnieu MC, Lardet G. Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA). Ther Drug Monit 2005; 27:457-462.

37. Jauregui Presa I. H1 antihistamines: a review. Allergol Immunol Clin 2004; 14:300-312.

38. Morgan MW, Khan D, Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 2005; 39:2056-2064.

39. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61:246-255.

40. Leroux M, Budnik D, Hall K, Irvine-Meek J, Otten N, Seshia S. Comparison of gas-liquid chromatography and EMIT assay for serum valproic acid. Clin Biochem 1981; 14:87-90.

41. Loscher W. Rapid determination of valproate sodium in serum by gas-liquid chromatography. Epilepsia 1977; 18:225-227.

42. Webb T. Identification of interference affecting the gas-liquid chromatography analysis of valproic acid in quality control material. Pathology 1986; 18:307-309.

43. Flanagan RJ, Withers G. A rapid micro-method for the screening and measurement of barbiturates and related compounds in plasma by gas-liquid chromatography. J Clin Pathol 1972; 25:899-904.

44. Ammann H, Vinet B. Accuracy, precision, and interferences of three modified EMIT procedures for determining serum phenobarbital, urine morphine, and urine cocaine metabolite with a Cobas-Fara. Clin Chem 1991; 37:2139-2141.

45. Nordt SP. Butalbital cross-reactivity to an Emit assay for phenobarbital. Ann Pharmacother 1997; 31:254-255.

Dealing With Asthma Naturally

Dealing With Asthma Naturally

Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally

Get My Free Ebook


Post a comment